The beneficial effects of intervention in early renal disease

Nephrology Dialysis Transplantation

Volumn 16, Issue SUPPL. 2, 2001, Pages 12-15

  Portolés, José ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

Author keywords

Anaemia; Epoetin; Left ventricular hypertrophy; Pre dialysis; Progressive renal insufficiency

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DIALYSIS; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; SMOKING CESSATION;

EID: 0034999329     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/16.suppl_2.12     Document Type: Article

References (32)

1. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity and mortality in end-stage renal disease. Am J Kidney Dis 1996; 28: 53-61
2. Sarnak MJ, Levey AS. Cardiovascular disease and chronic renal disease: a new paradigm. Am J Kidney Dis 2000; 35 [4 Suppl 1]: S117-S131
3. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 1999; 10: 610-619
4. Locatelli F, Conte F, Marcelli D. The impact of haematocrit levels and erythropoetin treatment on overall and cardiovascular mortality and morbidity - the experience of the Lombardy Dialysis Registry. Nephrol Dial Transplant 1998; 13: 1642-1644
5. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125-134
6. Foley RN, Parfrey PS, Harnett JD et al. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186-192
7. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention. Am J Kidney Dis 1996; 27: 347-354
8. Ritz E, Amann K. Optimal haemoglobin during treatment with recombinant human erythropoietin. Nephrol Dial Transplant 1998; 13 [Suppl 2]: 16-22
9. Macdougall IC, Lewis NP, Saunders MJ et al. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990; 335: 489-493
10. Pascual J, Teruel JL, Moya JL, Liano F, Jimenez-Mena M, Ortuno J. Regression of left ventricular hypertrophy alter partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35: 280-287
11. Zehnder C, Zuber M, Sulzer M et al. Influence of long-term amelioration of anemia and blood pressure control on left ventricular hypertrophy in hemodialyzed patients. Nephron 1992; 61: 21-25
12. Wizeman V, Schafer R, Kramer W. Follow-up of cardiac changes induced by anemia compensation in normotensive hemodialysis patients with left-ventricular hypertrophy. Nephron 1993; 64: 202-206
13. Massimetti C, Pontillo D, Feriozzi S, Costantini S, Capezzuto A, Ancarani E. Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients. Blood Purif 1998; 16: 317-324
14. Jeren-Strujić B, Raos V, Jeren T, Horvatin-Godler S. Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin. Angiology 2000; 51: 131-139
15. Albertazzi A, Di Liberato L, Daniele F, Battistel V, Colombi L. Efficacy and tolerability of recombinant human erythropoietin treatment in predialysis patients: results of a multicenter study. Int J Artif Organs 1998; 21: 12-18
16. Austrian Multicenter Study Group of rHuEPO in Predialysis. Effectiveness and safety of rHuEPO in predialysis patients. Nephron 1992; 61: 399-403
17. Koch KM, Koene RAP, Messinger D, Quarder O, Scigalla P. The use of epoetin beta in anemic predialysis patients with chronic renal failure. Clin Nephrol 1995; 44: 201-208
18. US Recombinant Human Erythropoietin Predialysis Study Group. Double-blind, placebo-controlled study of the therapeutic use of rHuEPO for anemia associated with chronic renal failure in predialysis patients. Am J Kidney Dis 1991; 18: 50-59
19. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14 [Suppl 5]: 1-50
20. Portolés J, Torralbo A, Martin P, Rodrigo J, Herrero JA, Barrientos A. Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 1997; 29: 541-548
21. Delano BG. Improvements in quality of life following treatment with r-HuEPO in anemic hemodialysis patients. Am J Kidney Dis 1989; 14 [Suppl 1]: 14-18
22. Evans RW, Rader B, Manninen DL. For the Cooperative Multicenter EPO Clinical Trial Group. The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. JAMA 1990; 263: 825-830
23. McMahon LP, McKenna MJ, Sangkabutra T et al. Physical performance and associated electrolyte changes after haemoglobin normalization: a comparative study in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1182-1187
24. Möcks J, Franke W, Ehmer B, Quarder O, Scigalla P. Analysis of safely database for long-term epoetin beta treatment: a meta analysis covering 3697 patients. In: Koch KM, Stein G, eds. Pathogenetic and Therapeutic Aspects of Chronic Renal Failure. Marcel Dekker Inc., New York, 1997: 163-179
25. Stivelman JC. Benefits of anaemia treatment on cognitive function. Nephrol Dial Transplant 2000; 15 [Suppl 3]: 29-35
26. Clyne N, Jorgenstrand T. Effect of erythropoietin treatment on physical exercise capacity and on renal function in predialytic uremic patients. Nephron 1992; 60: 390-396
27. Lim VS, DeGowin RL, Zavala D et al. Recombinant human erythropoietin treatment in pre-dialysis patients: a double-blind placebo-controlled trial. Ann Intern Med 1989; 110: 108-114
28. Revicki DA, Brown E, Feeny DH et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995, 25: 548-554.
29. Ritz E, Eisenhardt A. Early epoetin treatment in patients with renal insufficiency. Nephrol Dial Transplant 2000; 15 [Suppl 3]: 40-44
30. Valderrábano F. Quality of life benefits of early anaemia treatment. Nephrol Dial Transplant 2000; 15 [Suppl 3]: 23-28
31. Hayashi T, Suzuki A, Shoji T et al. Cardiovascular effect of normalizing the hematocrit level during erythropoietin therapy in predialysis patients with chronic renal failure. Am J Kidney Dis 2000; 35: 250-256
32. Valderrábano F (on behalf of Spanish Group for the Study of anaemia and left ventricular hypertrophy in predialysis patients). Improvement and prevention of left ventricular hypertrophy in predialysis patients [abstract]. Nephrol Dial Transplant 2000; 15: A115